Treatment for metastatic nasopharyngeal carcinoma

被引：136

作者：

Bensouda, Y. ^{[1
]}

Kaikani, W. ^{[1
]}

Ahbeddou, N. ^{[1
]}

Rahhali, R. ^{[1
]}

Jabri, M. ^{[2
]}

Mrabti, H. ^{[1
]}

Boussen, H. ^{[3
]}

Errihani, H. ^{[1
]}

机构：

[1] Inst Natl Oncol, Med Oncol Serv, Rabat, Morocco

[2] Hop Specialites, Serv Chirurg Maxillofaciale, Rabat, Morocco

[3] Inst Salah Azaiz, Dept Med Oncol, Tunis, Tunisia

来源：

EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES | 2011年 / 128卷 / 02期

关键词：

Nasopharyngeal carcinoma; Metastatic; Chemotherapy; Targeted therapy; PHASE-II TRIAL; UNDIFFERENTIATED CARCINOMA; 1ST-LINE CHEMOTHERAPY; ASIAN PATIENTS; RECURRENT; CISPLATIN; GEMCITABINE; 5-FLUOROURACIL; COMBINATION; CARBOPLATIN;

D O I：

10.1016/j.anorl.2010.10.003

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Nasopharyngeal carcinoma (NPC) is a specific entity different from head and neck carcinoma. Incidence is higher in South-East Asia and North Africa. Prognosis, especially for locally advanced stages (IIB - IVB) and metastasis, remains poor: more than third of cases will present local and/or metastatic recurrence. Overall 5-year survival for all NPC stages ranges from 50% to 70%. The role of chemotherapy in metastasis is well established, and remains an important palliative treatment, although no randomized trial has been reported comparing the different chemotherapy regimens. As 1st-line treatment, platin-based regimens seems optimal; in 2nd line and after progression under platins, there is no consensus: monotherapy with drugs such as gemcitabine, capecitabine or taxanes has been the most widely tested, with acceptable results. Future trials should integrate targeted therapy, in the light of overexpression of EGFR1 and C-kit in NPC. The present study presents a review of the literature concerning the various studies of metastatic NPC. (C) 2010 Elsevier Masson SAS. All rights reserved.

引用

页码：79 / 85

页数：7

共 56 条

[1] DISTANT METASTASES OF NASOPHARYNGEAL CARCINOMA - A STUDY OF 256 MALE-PATIENTS [J].